Login to Your Account

NewCo News

Milo Aims Follistatin Therapy at Muscular Dystrophy

By Marie Powers
Staff Writer

Tuesday, April 2, 2013

Just a year out of the gate and with less than $1 million in funding, Milo Biotechnology LLC already has an FDA-sanctioned investigational new drug (IND) application and is in human trials with follistatin, a protein that increases muscle strength and prevents atrophy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription